Holen Sie sich die Stockscreener-App
9.905
72.91%
-26.66
Handel nachbörslich:
10.05
0.145
+1.46%
Maplight Therapeutics Inc Aktie (MPLT) Neueste Nachrichten
MapLight Therapeutics Inc (MPLT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose - Yahoo Finance
Morgan Stanley downgrades MapLight Therapeutics stock rating on trial results - Investing.com
Wolfe cuts MapLight Therapeutics stock price target on trial data - Investing.com
Wolfe cuts MapLight Therapeutics stock price target on trial data By Investing.com - Investing.com Canada
MapLight’s ZEPHYR Trial Hits Endpoints In Schizophrenia, But Investors Want To See More - insights.citeline.com
MapLight Therapeutics' Lead Candidate Falls Meaningfully Short In Schizophrenia (MPLT) - Seeking Alpha
MapLight’s Schizophrenia Candidate Has Mixed Results at Phase II - Inside Precision Medicine
Biotech And AI Stocks Got Hit On Mixed News - Finimize
Maplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary Endpoint - MarketBeat
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
MapLight Therapeutics (MPLT) Faces Stock Decline Despite Positiv - GuruFocus
MapLight sinks as Cobenfy challenger falls short on once-daily goal - FirstWord Pharma
MapLight dives despite positive data for schizophrenia drug - BioPharma Dive
Maplight aims to differentiate muscarinic agonist from competitors - BioWorld News
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law - Business Wire
Maplight Therapeutics (NASDAQ:MPLT) Sets New 12-Month LowTime to Sell? - MarketBeat
MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout - BioSpace
MapLight Therapeutics stock holds Buy rating at TD Cowen after trial data - Investing.com
Jefferies reiterates MapLight Therapeutics stock rating on trial data - Investing.com
Raymond James cuts MapLight Therapeutics stock price target on efficacy data - Investing.com Canada
Jefferies reiterates MapLight Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
BMO reiterates Outperform on MapLight stock after trial data By Investing.com - Investing.com Canada
MapLight’s schizophrenia drug fails once-daily test, shares plunge - 101 WIXX
BMO reiterates Outperform on MapLight stock after trial data - Investing.com
Stifel reiterates MapLight Therapeutics stock rating on schizophrenia data By Investing.com - Investing.com Canada
Stifel reiterates MapLight Therapeutics stock rating on schizophrenia data - Investing.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
MPLT: ML-007C-MA met key efficacy and safety endpoints in Phase 2 schizophrenia trial, supporting Phase 3 plans - TradingView
Maplight Therapeutics Announces Positive Topline Results from Phase 2 Zephyr Trial of Ml-007C-Ma in Schizophrenia - marketscreener.com
MapLight Therapeutics stock tumbles 50% on mixed phase 2 schizophrenia data (MPLT:NASDAQ) - Seeking Alpha
MapLight schizophrenia drug meets phase 2 trial primary endpoint - Investing.com
MapLight Therapeutics stock tumbles 40% on trial results - Investing.com
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia - The Manila Times
MapLight Therapeutics (Nasdaq: MPLT) hits key Phase 2 goal in schizophrenia - Stock Titan
MapLight Therapeutics Inc (MPLT) Institutional Confidence - TradingKey
MapLight Therapeutics Inc (MPLT) Cash Flow - TradingKey
MPLT|MapLight Therapeutics Inc|Price:9.910|Chg%:-26.650 - TradingKey
MapLight Therapeutics Inc (MPLT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
MapLight Therapeutics (MPLT) Rally Puts Its CNS Story And Valuation In Focus - simplywall.st
MPLT|MapLight Therapeutics Inc|Price:36.560|Chg%:+1.330 - TradingKey
Is MapLight Therapeutics (MPLT) Fully Valued As Its Shares Hold Near $36.56? - Yahoo! Finance Canada
MapLight Therapeutics, Inc. Revenue Breakdown – NASDAQ:MPLT - TradingView
MAPLIGHT THERAPEUTICS INC : CANACCORD GENUITY RAISES TARGET PRICE TO $43 FROM $35 - webull.com
Canaccord raises MapLight Therapeutics price target on trial data By Investing.com - Investing.com South Africa
Canaccord raises MapLight Therapeutics price target on trial data - Investing.com
Possible Bearish Signals With MapLight Therapeutics Insiders Disposing Stock - simplywall.st
Craig-Hallum initiates coverage of MapLight Therapeutics (MPLT) with buy recommendation - MSN
Wall Street Analysts Are Bullish on Top NA Picks - The Globe and Mail
Maplight Therapeutics (NASDAQ:MPLT) Upgraded by BMO Capital Markets to Strong-Buy Rating - MarketBeat
Form 4 MapLight Therapeutics Inc For: 21 July By Investing.com - Investing.com South Africa
MapLight Therapeutics CSO James Woodruff sells $673k in shares for tax - Investing.com UK
UBS raises MapLight Therapeutics stock price target on trial data By Investing.com - Investing.com Nigeria
MapLight Therapeutics Seen Having Upside in Schizophrenia Trial Readout, UBS Says - marketscreener.com
BMO Capital Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Maintains Target Price $46 - Moomoo
UBS Adjusts MapLight Therapeutics Price Target to $52 From $48, Maintains Buy Rating - Moomoo
MapLight Therapeutics CEO Kroeger sells $5.4m in company stock By Investing.com - Investing.com Australia
MPLT Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
UBS raises MapLight Therapeutics stock price target on trial data - Investing.com
MapLight Therapeutics general counsel sells $607,870 in shares By Investing.com - Investing.com South Africa
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):